Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of a shiny sun and gentle breeze passing by the quiet Pharmalot campus. Our shortest person is sleeping in today, since the local schoolhouse is closed for a needed break, and our other short one has left for the daily round of gainful employment. This leaves us to tend to the coffee kettle and usual task of foraging for interesting items. Speaking of which, here are a few. Hope your day is rewarding nd meaningful. And as always, do keep in touch. …

Gilead Sciences (GILD) will partner with privately held Insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drug maker tries to overcome its recent setback in developing NASH treatments, STAT writes. Insitro will receive $15 million, and up to $1 billion more down the line if it meets certain goals, and the deal — its first with a drug maker — offers a test of whether artificial intelligence can remake drug development. Last week, Gilead signed a deal with Novo Nordisk (NVO) to pursue a NASH treatment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy